Form 4: VYNE CFO Disposes Shares for Tax Withholding

VYNE Therapeutics Inc.'s CFO, Tyler Zeronda, reported a disposition of 3,420 common shares to satisfy tax withholding obligations related to restricted stock unit vesting.

Summary

• Tyler Zeronda, Chief Financial Officer of VYNE Therapeutics Inc., reported a transaction on September 30, 2025.
• The transaction involved the disposition of 3,420 shares of VYNE common stock.
• These shares were withheld by the Issuer to satisfy tax withholding requirements.
• The disposition was in connection with the vesting of restricted stock units.
• The price per share for the disposition was $0.335.
• Following this transaction, Mr. Zeronda directly beneficially owns 111,653 shares of common stock.

Sentiment

Score: 5

Explanation: This is a neutral, routine insider transaction for tax purposes, not indicative of positive or negative company performance or outlook.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine, non-discretionary transaction for tax purposes related to executive compensation.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

VYNE Therapeutics, VYNE, Tyler Zeronda, CFO, Form 4, Insider Transaction, Share Disposition, Tax Withholding, Restricted Stock Units, Equity Compensation